(("neoplasms"[MH] OR cancer[TW]) OR sloan-kettering AND Milowsky M[AU])

Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.

David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM.

Cancer. 2009 Apr 1;115(7):1435-47.

PMID: 19215030 [PubMed - indexed for MEDLINE]

Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer.

Milowsky MI, Stadler WM, Bajorin DF.

BJU Int. 2008 Nov;102(9 Pt B):1339-44. Review.

PMID: 19035902 [PubMed - indexed for MEDLINE]

Detection of circulating tumor cells in patients with urothelial cancer.

Gallagher DJ, Milowsky MI, Ishill N, Trout A, Boyle MG, Riches J, Fleisher M, Bajorin DF.

Ann Oncol. 2009 Feb;20(2):305-8. Epub 2008 Oct 3.

PMID: 18836088 [PubMed - indexed for MEDLINE]

A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.

Dash A, Pettus JA 4th, Herr HW, Bochner BH, Dalbagni G, Donat SM, Russo P, Boyle MG, Milowsky MI, Bajorin DF.

Cancer. 2008 Nov 1;113(9):2471-7.

PMID: 18823036 [PubMed - indexed for MEDLINE]

Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience.

Donat SM, Shabsigh A, Savage C, Cronin AM, Bochner BH, Dalbagni G, Herr HW, Milowsky MI.

Eur Urol. 2008 Jul 14. [Epub ahead of print]

PMID: 18640770 [PubMed - as supplied by publisher]

Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.

Gallagher DJ, Milowsky MI, Bajorin DF.

Cancer. 2008 Sep 15;113(6):1284-93. Review.

PMID: 18629841 [PubMed - indexed for MEDLINE]

Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.

Boorjian SA, Milowsky MI, Kaplan J, Albert M, Cobham MV, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM.

J Immunother. 2007 Sep;30(6):655-62.

PMID: 17667529 [PubMed - indexed for MEDLINE]

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.

David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM.

J Urol. 2007 Aug;178(2):451-4. Epub 2007 Jun 11.

PMID: 17561135 [PubMed - indexed for MEDLINE]

Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach.

Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D, Menon M.

J Urol. 2007 Mar;177(3):911-5. Erratum in: J Urol. 2007 May;177(5):1958.

PMID: 17296374 [PubMed - indexed for MEDLINE]

10:

Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH.

J Clin Oncol. 2007 Feb 10;25(5):540-7.

PMID: 17290063 [PubMed - indexed for MEDLINE]

11:

Chemotherapy for non-clear-cell renal cell carcinoma.

David KA, Milowsky MI, Nanus DM.

Clin Genitourin Cancer. 2006 Mar;4(4):263-8. Review.

PMID: 16729909 [PubMed - indexed for MEDLINE]

12:

Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.

David KA, Milowsky MI, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH.

Clin Genitourin Cancer. 2006 Mar;4(4):249-56. Review.

PMID: 16729907 [PubMed - indexed for MEDLINE]

13:

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7195s-7200s.

PMID: 16203821 [PubMed - indexed for MEDLINE]

14:

Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.

Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ.

J Clin Oncol. 2005 Jul 20;23(21):4591-601. Epub 2005 Apr 18.

PMID: 15837970 [PubMed - indexed for MEDLINE]

15:

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.

Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP.

Cancer. 2004 Oct 1;101(7):1545-51.

PMID: 15378501 [PubMed - indexed for MEDLINE]

16:

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH.

J Clin Oncol. 2004 Jul 1;22(13):2522-31. Epub 2004 Jun 1.

PMID: 15173215 [PubMed - indexed for MEDLINE]

17:

Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.

Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH.

J Urol. 2003 Dec;170(6 Pt 2):S84-8; discussion S88-9. Review.

PMID: 14610416 [PubMed - indexed for MEDLINE]

18:

Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ.

Semin Oncol. 2003 Oct;30(5):667-76. Review.

PMID: 14571414 [PubMed - indexed for MEDLINE]

19:

Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ.

J Urol. 2003 Nov;170(5):1717-21.

PMID: 14532761 [PubMed - indexed for MEDLINE]

20:

Chemotherapeutic strategies for renal cell carcinoma.

Milowsky MI, Nanus DM.

Urol Clin North Am. 2003 Aug;30(3):601-9, x. Review.

PMID: 12953758 [PubMed - indexed for MEDLINE]

Recent Activity